MaxCyte, Inc. (Nasdaq: MXCT) announced a Strategic Platform License Agreement with Anocca AB, a clinical-stage T-cell immunotherapy company, to advance the development and manufacturing of T-cell receptor engineered T-cell (TCR-T) therapies. The partnership will leverage MaxCyte's Flow Electroporation technology and ExPERT platform to support non-viral gene editing in Anocca's therapeutic pipeline.
Strategic Technology Partnership
Under the licensing agreement, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue from the partnership.
"We're proud to partner with Anocca as they advance the development of TCR-T therapeutics through the clinic," said Maher Masoud, President and CEO of MaxCyte. "We look forward to supporting Anocca with our globally supported, regulatory-proven platform and technical expertise to accelerate clinical manufacturing and cell engineering processes."
Manufacturing Capabilities and Clinical Pipeline
Anocca recently received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility. The company's lead program targets mutant KRAS-driven advanced pancreatic cancer and is currently in clinical development.
The addition of MaxCyte's ExPERT platform provides Anocca with a scalable technology platform designed to enhance its ability to deliver gene-edited cell therapies. According to Masoud, the ExPERT platform "delivers the robust scalability and flexibility needed to power high-performance, non-viral gene editing workflows across Anocca's diverse therapeutic pipeline."
Technology Platform Advantages
MaxCyte's Flow Electroporation technology enables precise, efficient and scalable cell engineering for next-generation cell therapies. The company's platform has been supporting cell engineering research for more than 25 years, providing scientific, technical and regulatory guidance to researchers developing cell-based treatments.
The partnership represents MaxCyte's continued expansion in the cell therapy manufacturing space, where its non-viral gene editing approach offers an alternative to viral-based methods for engineering therapeutic cells. The technology platform is designed to support the engineering of diverse cell types and payloads across various therapeutic applications.
